NEWBORN CALF SERUM MARKET ANALYSIS

Newborn Calf Serum (NBCS) is developed from 3 to 10 days old calves. NBCS is cheaper and better in quality than fetal bovine serum. As newborn calf serum (NBCS) is more affordable and commonly available, it is preferred as a basal growth medium over fetal bovine serum. When a cell line is tough and cell attachment is a major concern during cell culture, newborn calf serum is often used. Some more advantages of newborn calf serum are:

• NBCS performance is good where regular cell growth and cell maintenance are the objective
• NBCS is rich in antibodies used for the development of immune system
• NBCS contains a high proportion of immunoglobin and protein
• In mouse spermatogonial stem cells, use of NBCS increase the viability after cryopreservation

Global Newborn Calf Serum Market - Impact of the Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic is expected to drive the growth of the global newborn calf serum market, owing to an increase in research and development activities related to vaccine production. For instance, in 2020, Bharat Biotech, a biotechnology company, had conducted research for the production of COVID-19 vaccine, in which newborn calf serum was used as one of the key ingredient for growing the vero cells lines. These cell lines were used in the manufacturing process of vaccines. Cell culture is done for testing the capacity, nature, etc. of vaccine agents.

Increasing in number of clinical trials for new drug discovery, after COVID-19, is expected to drive the growth of the global newborn calf serum market over the forecast period. For instance, in 2020, Frontiers journal published a review article on clinical trials done after COVID-19. According to the published data, there was a great increase in clinical trials for the development of new drugs. Before clinical trials new drugs are tested on cell lines, these cell lines are grown with the use of serum, as one of the key ingredient in growing medium. Increasing number of clinical trials indicates use of cell lines in large amount, which is expected to increase the use of new born calf serum.

The global newborn calf serum market is estimated to be valued at US$ 222.2 Mn in 2022 and is expected to exhibit a CAGR of 6.8% over the forecast period (2022-2030).

Figure 1: Global Newborn Calf Serum Market Share, (%), Analysis, By Origin, 2022

To learn more about this report, request sample copy

Pharmaceutical companies have started investing in the production of newborn calf serum. This is expected to propel the growth of the global newborn calf serum market over the forecast period.

Market players are investing in manufacturing unit to increase their manufacturing capacity, this is expected to drive the growth of global newborn calf serum market. For instance, in January 2018, Indian Immunologicals Limited, an animal and human vaccine manufacturer started its new manufacturing plant with wholly owned its subsidiary Pristine Biologicals (NZ) Ltd. in New Zealand with the investment of US$1 million. Among all the product, newborn calf serum is one of the key product manufactured by this new manufacturing plant. Indian Immunological Limited as invested in this because it want a control over the key ingredient used for the manufacturing of vaccines.

Key players are involved in expanding their services for cell therapy, which is expected to drive the growth of the global newborn calf serum market over the forecast period.

Newborn calf serum is a key ingredient in cell culture. Market players are investing in large scale in cell culture research. Companies are expanding their services toward cell therapy, therefore, these factors are expected to increase the use of newborn calf serum in future which will boost the growth of global newborn calf serum market. For instance, in June 2022, NorthX Biologics, a biologics company with the help of Alder Therapeutics, a pharmaceutical company expanded its services for cell therapy and established Good Manufacturing Practice (GMP)-manufacturing labs at Matfors facility and Karolinska University Hospital campus in Stockholm. NorthX is doing this expansion due to increasing needs of patients and growing cell therapies market.

Global Newborn Calf Serum Market – Restraints

Animal ethical committees are putting restrictions to the use of newborn calf serum for the production of vaccines, which may have a negative impact on the global newborn calf serum market. People for the Ethical Treatment of Animals (PETA) India in 2021 requested drug controller to replace newborn calf serum with animal-free media for the production of vaccines. According to the Prevention of Cruelty to Animals Rules, 2001, the slaughter of animals under the age of 3 months and pregnant animals is prohibited. Newborn calf serum is developed from newborn calf less than 20 days; therefore, PETA India urged to stop the use of newborn calf serum. The implementation of animal ethical committee rules and laws globally may bring down the newborn calf serum market growth, globally. Newborn calf serum has less growth factors than fetal bovine serum. This may reduce the interest of users to use newborn calf serum for cell culture, which also may have a bad impact on the global newborn calf serum market.

Global Newborn Calf Serum Market – Regional Analysis

On the basis of region, the global newborn calf serum market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa

Among regions, the North America newborn calf serum market is expected to hold a dominant position during the forecast period owing to an increase in vaccine production. For instance, in 2019, Merck & Company Incorporation, a pharmaceutical company increased its overall vaccine supply to 190 million doses worldwide. Apart from this, Merck had expanded its manufacturing capacity for helping Johnson & Johnson produce Covid-19 vaccine. Merck will use its facilities in the U.S. to produce drug substances, formulate, and fill vials of Johnson & Johnson’s vaccine.

The Europe newborn calf serum market was predicted to experience solid growth over the forecast period, owing to increase in collaboration with other market players. For Instance, on 25^th June 2022, BioNTech, a biotechnology company, and Pfizer Inc., a pharmaceutical and biotechnology corporation, collaborated and tested the safety, tolerability, and immunogenicity of one monovalent and one bivalent Omicron-adapted COVID-19 vaccine candidate and reported a positive result. Further, they are planning to discuss these results with scientific and health care authorities, which will enable them to launch Omicron-adapted booster in the market at the earliest.

Support by French government by providing interest free loan to develop independent biotech enterprises, whereby it is expected to drive the growth of newborn calf serum market. For instance, TreeFrog Therapeutics, a biotechnology company, founded in 2018 in France, received US$ 66.7654 M Series B investment in 2021, through which the company has started international expansion in its workforce and facilities for the development and production of cell therapies. The funding will be also used to develop biomimetic C-StemTM technology for clinical-grade production and expand and bring a wide range of cell therapies closer to the clinic.

The Asia Pacific newborn calf serum market is expected to exhibit the fastest growth during the forecast period, owing to increasing investment in life science sector. For instance, on June 28, 2022, Actis, a global investment firm, announced investment over US$ 700 million to develop life science realty asset in India. The investment is planned to build and develop assets under its platform aimed on providing real estate to clients in the life sciences and related sectors in India. Through which it is expected to boost the calf serum market.

Figure 2: Global Newborn Calf Serum Market (US$ Mn), by Region, 2022

To learn more about this report, request sample copy

Global Newborn Calf Serum Market – Competitive Landscape

Major players operating in the global newborn calf serum market include HiMedia Laboratories, Thermo Fisher Scientific Inc., Sartorius AG, Merck KGaA, Corning Inc., Atlas Biologicals, Inc., TCS Biosciences Ltd., Bovogen Biologicals Pty Ltd., Novus Biologicals, LLC, Capricorn Scientific, PAN-Biotech GmbH, Atlanta Biologicals, Inc., Rockey Mountain Biologicals, GE Healthcare, Serana, and Zhejiang Tianhang Biotechnology.